touchONCOLOGY joins Dr Julius Strauss (National Cancer Institute, National Institutes of Health, Bethesda, MD, USA), to discuss the long-term follow-up of patients with human papillomavirus–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1.
Questions
1. What are the unmet needs in the treatment of human papillomavirus (HPV)-associated cancers? (00:15-01:37)
2. What is bintrafusp alfa and what is the rationale for its use in this treatment setting? (01:37-02:49)
3. Could you tell us a little about the INTR@PID 001 study and its findings? (02:49-04:38)
4. What have we learned from the latest longer-term data from this study? (04:38-05:00)
5. What will be the next step in the clinical development of bintrafusp alfa in HPV-associated malignancies? (05:00-06:29)
Disclosures: Julius Strauss is listed as a co-inventor on an NIH patent evaluating dual blockade of TGFβ and PDL1 for HPV associated malignancies.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson
Filmed in coverage of the ESMO 2021 Annual Meeting.
